Preparation of piperazinyl quinazolines as 5-HT6 modulators.
2007 (English)Patent (Other (popular science, discussion, etc.))Text
Title compds. represented by the formula I [wherein Q = (hetero)arylalkyl; R1 = OH, halo, alkyl, etc.; R2, R3 = independently H, (halo)alkyl, aminocarbonylalkyl, etc.; n = 0-3; and pharmaceutically acceptable salts, solvates or solvated salts thereof] were prepd. as 5-HT6 modulators. For example, reaction of 2-chloro-4-(4-methylpiperazin-1-yl)quinazoline with N-methyl-4-chlorobenzenesulfonamide gave II in 10% yield. The radioligand binding assay showed II having Ki of 200 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of 5-HT6 mediated disorders, such as Alzheimer's disease, schizophrenia, obesity or Parkinson's disease. [on SciFinder(R)]
Place, publisher, year, edition, pages
AstraZeneca AB, Swed. . , 2007. no WO2007108744A2
quinazoline piperazinyl benzenesulfonamide prepn 5HT6 modulator, Alzheimer schizophrenia obesity Parkinson disease treatment piperazinylquinazolinyl benzenesulfonamide prepn
IdentifiersURN: urn:nbn:se:uu:diva-270236OAI: oai:DiVA.org:uu-270236DiVA: diva2:888187
CAPLUS AN 2007:1091014(Patent)2015-12-222015-12-222015-12-22